Skip to main content

Table 2 Demographic characteristics and medications: bivariate analysis

From: Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study

 

Total (n = 1084)

CLO

(n = 700)

CLO + VAL (n =319)

CLO + Li (n = 45)

CLO + VAL + Li(n = 20)

P value

Neutropenia

48 (4.4%)

20 (2.9%)

28 (8.8%)

0 (0.0%)

0 (0.0%)b

< .001 b

Leukocytosis

453 (41.8%)

277 (39.6%)

134 (42.0%)

32 (71.1%)

10 (50.0%)

< .001 b

Neutropenia + 

Leukocytosis

7 (0.6%)

5 (0.7%)

2 (0.6%)

0 (0.0%)

0 (0.0%)

.924b

Age

41.06 ± 12.81

42.03 ± 13.32

39.43 ± 11.69

40.63 ± 11.07

34.47 ± 11.71

.002 a

Daily clozapine dosage (mg)

242.08 ± 148.86

236.18 ± 

143.02

250.9 ± 

155.88

288.89 ± 

181.11

202.50 ± 

136.36

.044 a

Sex

      

Male

539 (49.7%)

310 (44.3%)

194 (60.8%)

24 (53.3%)

11 (55.0%)

< .001 b

Female

545 (50.3%)

390 (55.7%)

125 (39.2%)

21 (46.7%)

9 (45.0%)

 

Antipsychotics

325 (30.0%)

193 (27.6%)

115 (36.1%)

13 (28.9%)

4 (20.0%)

.037 b

First generation

antipsychotics

245 (22.6%)

146 (20.9%)

86 (27.0%)

10 (22.2%)

3 (15.0%)

.148b

Second generation antipsychotics

86 (7.9%)

52 (7.4%)

30 (9.4%)

3 (6.7%)

1 (5.0%)

.677b

Other mood-

stabilizers

      

Lamotrigine

8 (0.7%)

6 (0.9%)

1 (0.3%)

1 (2.2%)

0 (0.0%)

.489b

Oxcarbazepine

2 (0.2%)

1 (0.1%)

1 (0.3%)

0 (0.0%)

0 (0.0%)

.925b

Antidepressant

164 (15.1%)

119 (17.0%)

37 (11.6%)

7 (15.6%)

1 (5.0%)

.085b

Antidepressant total

dosage (DDD)

1.15 ± 0.91

1.13 ± 0.93

1.33 ± 0.85

0.66 ± 0.65

0.5

.252a

SSRI

111 (10.2)

79 (11.3)

30 (9.4)

1 (2.2)

1(5.0)

.185b

SSRI total

dosage (DDD)

1.41 ± 0.88

1.41 ± 0.91

1.44 ± 0.81

2.0

0.5

.676a

Anticholinergics

376 (34.7)

214 (30.6%)

139 (43.6%)

15 (33.3%)

8 (40.0%)

.001 b

Benzodiazepine

559 (51.6%)

339 (48.4%)

180 (56.4%)

28 (62.2%)

12 (60.0%)

.039 b

Antihypertensives

378 (34.9)

219 (31.3%)

127 (39.8%)

26 (57.8%)

6 (30.0%)

< .001 b

Antidiabetics

29 (2.7%)

17 (2.4%)

11 (3.4%)

1 (2.2%)

0 (0.0%)

.687b

Antihyperlipidemics

23 (2.1%)

11 (1.6%)

8 (2.5%)

4 (8.9%)

0 (0.0%)

.009 b

Antiepileptics

22 (2.0%)

13 (1.9%)

8 (2.5%)

1 (2.2%)

0 (0.0%)

.827b

  1. Bold p values indicate a statistically significant difference
  2. a: Continuous variables, displayed as mean ± standard deviation, were tested using one-way ANOVA
  3. b: Categorical variables, displayed as number (percentage), were tested using the chi-square test
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us